CytoSorbents (CTSO) Q3 2026 earnings review
CytoSorbents cuts its cash burn, but its debt comes due
CytoSorbents, a maker of blood purification cartridges for intensive care and heart surgery, nearly erased its operating cash burn through deep cost cuts even as sales in its core German market shrank. Revenue edged up 3% to $9.7 million on stronger distributor orders, while a 75% gross margin and lower overhead cut the operating loss by more than half. Chief executive Dr. Phillip Chan said the company reached its second-half goal of operating cash flow breakeven before restructuring costs.
| Revenue | $9.7M +2.6% from a year ago |
|---|---|
| Gross margin | 75% 70% a year ago |
| Operating cash flow (ex-restructuring) | $43K -$2.7M a year ago; -$267K on a GAAP basis by our math |
| Cash Flow Outlook | Unchanged Target: at or near breakeven |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because cutting operational burn does not solve the debt coming due in 2027. Lower sales and factory costs narrowed the loss before interest, taxes, depreciation and one-offs to $284,000, and August meetings with US regulators kept two 2027 blood-thinner filter filings on track. The bad news: all $17.5 million of debt moved to current liabilities against $5.7 million in total cash, and hitting cash breakeven relied on drawing down inventory.
The question now is whether the medical device maker can refinance its loan and keep cash burn near zero once inventory drawdowns end. Either distributor growth and lower costs cover cash interest and support a loan extension, or the company must raise dilutive equity before principal payments begin in 2027. Fourth-quarter cash flow and any year-end financing deal will settle it.
🐂 Bull Case
Lower Sales Costs and Factory Gains Cut the Loss
CytoSorbents spent the past year cutting its workforce by 24% and improving how it sources materials and makes its blood purification cartridges. Chief executive Dr. Phillip Chan said this leaner setup will let future revenue growth flow into profit.
- Selling, general and administrative expense (sales and overhead): 73.0% of revenue, down 17.8 percentage points from a year ago by our math
- Cost of goods sold (cost of making the products): 24.7% of revenue, down 5.1 percentage points from a year ago by our math
- Gross margin: 75.3%, up from 73.2% last quarter and 70.3% a year ago
- Operating loss: $1.2 million, narrowed by 59% from $2.9 million a year ago
The cost cuts worked as planned because overhead fell $1.5 million from a year ago while revenue rose slightly. That combination shrank the loss before interest, taxes, depreciation and one-offs by 86% to $284,000, bringing the core operation much closer to covering its own bills.
What to watch: selling and overhead expenses over the next two quarters as 5 new German sales reps join the payroll. Rising overhead without a matching lift in German hospital orders would widen the operating loss again.
Distributor Sales Carry the Top Line
Outside Germany, the medical device maker sells its CytoSorb blood filters through independent distributors, strategic partners, and its own direct reps in other countries. Together, those markets now bring in 76% of total revenue.
Sales to distributors and partners grew 16% from a year ago in the financial summary (18% in Chan's commentary) and rose 10% from last quarter. Direct sales outside Germany increased 4% from a year ago, lifting total revenue 2.6% to $9.7 million despite the slump in Germany.
What to watch: customer concentration in the upcoming quarterly filing. If two distributors still drive more than a quarter of revenue as they did last quarter, this growth channel remains vulnerable to uneven ordering.
Two FDA Tracks Advance Toward 2027 Filings
CytoSorbents wants US approval for DrugSorb-ATR, a cartridge that removes blood-thinning drugs during urgent heart surgery to stop severe bleeding. Meanwhile, the company is seeking government grants or partners for HemoDefend-BGA, an experimental filter that creates universal plasma, after receiving FDA feedback in July.
In August, the company held two pre-submission meetings with the FDA and presented a 587-patient heart-surgery study on the blood thinner Brilinta showing a 37% relative drop in severe bleeding. It is now finalizing an "animal study protocol with the FDA to collect additional mechanistic data" for a Brilinta filing in early 2027, alongside a second 2027 filing for the blood thinners Eliquis and Xarelto.
What to watch: completion of the animal study and the formal Brilinta submission in early 2027. Any further delay would leave the company without a US regulatory decision while its debt matures.
🐻 Bear Case
Cash Breakeven Rested on Inventory Drawdowns
"The third quarter marked an important financial milestone for CytoSorbents as we achieved our goal of operating cash flow breakeven, excluding restructuring-related payments," chief executive Dr. Phillip Chan said. He pointed to $43,000 of positive operating cash flow before $251,000 of severance and restructuring payouts.
Standard accounting figures and balance sheet movements tell a tighter story. By our math from the nine-month cash flow statement, standard operating cash flow in the third quarter was negative $267,000, or negative $16,000 before restructuring payments.
- Loss before interest, taxes, depreciation and one-offs: $284,000
- Cash paid for interest in Q3: about $653,000 by our math
- Inventory on the balance sheet: $3.2 million, down $459,000 in Q3 and down $2.1 million since year-end
Before working capital shifts, the business still lost about $937,000 in cash this quarter by our math because operating profit does not yet cover cash interest. Selling down stock built up last year bridged the gap, and inventory is now near historic lows.
What to watch: operating cash flow in the fourth quarter as inventory drawdowns slow. Without higher revenue, slowing inventory releases will push quarterly cash flow back into a deficit.
Entire Debt Load Moves to Due Within One Year
CytoSorbents owes $17.5 million in carrying value under its term loan, which matures on July 1, 2027. Extending the interest-only period into 2027 and unlocking a new $2.5 million loan tranche required FDA approval of DrugSorb-ATR in 2026, which will not happen with the filing set for early 2027.
On the September 30 balance sheet, long-term debt dropped to zero and current maturities of debt rose to $17.5 million, up from $14.1 million in June. At the same time, total cash (including $1.5 million of restricted cash) dipped to $5.7 million, and stockholders' deficit widened from $752,000 to $2.3 million.
Because unrestricted cash is $4.2 million and the entire loan comes due within ten months, the company does not have the cash on hand to make scheduled principal payments in 2027. Even zero operating cash burn leaves the principal wall untouched.
What to watch: a debt refinancing, loan amendment, or equity raise before principal payments start in January 2027. A deal before year-end will show how much dilution or extra interest cost shareholders must absorb.
Germany Direct Sales Keep Shrinking
Germany is the company's largest direct market, bringing in 24% of quarterly revenue. Rebuilding sales there after a commercial reorganization is one of Chan's four main priorities.
German sales fell 20% from a year ago in the third quarter, following a 24% drop in the second quarter, which Chan blamed on a "smaller, more focused sales force and reduced territory coverage". To fix it, the company hired Alex Tiefenbacher as senior vice president of direct sales, added two German reps, and plans to hire three more by early 2027.
What to watch: German revenue growth in the first half of 2027 once all five new reps are in the field. A smaller decline will show whether the problem was simply too few reps rather than lower hospital demand.
Risks this quarter didn't answer
Three standing risks from prior quarters received no new numbers in the third-quarter press release.
- Distributor concentration: two distributors made up 28% of sales last quarter; the quarterly filing's credit-risk note will show if the third-quarter distributor jump relied on the same two buyers.
- Middle East order disruptions: war in the region delayed $500,000 of orders earlier this year; the filing or call will show whether those shipments resumed.
- Currency effects on revenue: European sales are billed in euros and reported in dollars; the filing will show growth at constant exchange rates.
👓 Other Themes
Reverse Split Executed and Restructuring Extended
CytoSorbents completed a 1-for-20 reverse stock split on September 8, 2026 to address Nasdaq listing rules, shrinking its share count to 3.15 million and adjusting all historical per-share figures. Separately, the company booked $250,000 in new restructuring charges and paid out $251,000 in restructuring cash during the third quarter, extending a workforce reduction programme that began in late 2025.
💲 Other KPIs
Uncollected customer bills rose 4.2% from last quarter to $7.07 million, growing faster than the 1.0% rise in quarterly revenue. Since December 2025, net receivables have fallen 6.4%, while the allowance for doubtful accounts — money set aside for bills customers may not pay — grew from $164,000 to $416,000.
Spending on clinical trials and regulatory work rose 24.7% from a year ago to $1.15 million, or 11.8% of revenue. From last quarter, research spending fell 21.2% from $1.45 million as the blood-purification developer wrapped up data analysis for its August heart-surgery presentation and FDA meetings.
Weighted average shares outstanding stood at 3.15 million after adjusting for the 1-for-20 reverse stock split completed in September, up 0.3% from 3.14 million a year ago. With no equity offerings during the first nine months of 2026, share count growth came only from employee stock awards.
🔮 Guidance
Unchanged. After reporting $43,000 of positive operating cash flow before restructuring payments in the third quarter, chief executive Dr. Phillip Chan said the company's goal is "sustaining operating cash flow at or near breakeven while selectively investing to accelerate sales growth". He noted that quarterly cash flow may fluctuate with the timing of sales, customer collections, and working capital.
Unchanged. The US regulatory filing for removing the blood thinner Brilinta during heart surgery remains set for early 2027, following three delays since late 2024. The submission will add a 587-patient real-world study expanding the treated patient count fivefold to about 250, plus an animal study now being finalized with the FDA.
Unchanged. The plan now specifies five additions — two sales representatives already hired, one joining in December, and two more arriving by early 2027 — hitting the top end of last quarter's three-to-five target to rebuild German hospital coverage.
❓ Key Questions
How will CytoSorbents pay or refinance the $17.5 million loan?
All $17.5 million of carrying debt is now classified as due within one year against $4.2 million in unrestricted cash, and the 2026 FDA approval needed to extend the interest-only period will not happen on time.
Why do the highlights and commentary give different distributor growth?
The financial highlights bullet states that distributor and strategic partner sales grew 16% from a year ago, while the chief executive's commentary states they grew 18%.
Did two distributors still drive the partner sales increase?
In the second quarter, two distributors accounted for 28% of total company revenue. Investors need to know whether the third-quarter gain came from broader hospital demand or orders from those same two partners.
How long will the FDA animal study take to run?
The company is still finalizing the animal study protocol with the FDA in November. Completing the protocol, running the study, and writing the report before an early 2027 submission leaves a tight schedule.